Recent news on Respigam

British Firm Agrees to Buy MedImmune  -  Apr 23, 2007
Washington Post,The company faced the possibility of going under after one of its drugs, RespiGam, was denied approval by a Food and Drug Administration advisory panel in

Stakeholder Opinions: Respiratory Syncytial Virus (RSV) - A market ...  -  Jan 17, 2007
Pharmaceutical Business ReviewAs RespiGam's successor, Synagis was first launched in 1998 and now has sales of around $750 million per RSV season. Due to its high costs though,

Stakeholder Opinions: Respiratory Syncytial Virus (RSV) - A market ...  -  Dec 20, 2006
Pharmaceutical Business ReviewAs RespiGam's successor, Synagis was first launched in 1998 and now has sales of around $750 million per RSV season. Due to its high costs though,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional